

Cala Partners with SK Biopharmaceuticals to Fuel Innovation in Neurology

The collaboration will enable opportunities to explore solutions for new indications in neurology

SAN MATEO, CA -- May 18, 2022 -- [Cala Health](#), the bioelectronic medicine leader setting a new standard of patient care for chronic disease, today announces an investment and potential collaboration with [SK Biopharmaceuticals, Co., Ltd.](#) and its parent company, [SK Inc.](#), to fuel innovation and new indications in neurology.

This partnership marks the first time SK Biopharmaceuticals are investing in the US, paving the way for further strategic partnership and investment in the world's largest biotech and healthcare market.

"We are pleased a global leader like SK Biopharmaceuticals have chosen Cala as their first US digital healthcare investment partner," said Renee Ryan, CEO of Cala. "Together, we will accelerate the realization of our shared vision of developing treatments and driving innovation to help more patients struggling with neurologic disorders."

The investment further solidifies Cala as the leader of bioelectronic medicine. In the past year, Cala has expanded its [commercial executive leadership team](#), achieved numerous [reimbursement milestones](#), announced [multiple clinical research studies](#) validating the efficacy of Cala TAPS therapy, and closed a successful Series D fundraising round.

"We are excited to forge a strategic partnership with Cala in bioelectronic medicine, and further support our common goal of spurring innovation and improving patients' lives. SK Biopharmaceuticals will not only work closely with SK Inc., but also global partners as we seek to provide total healthcare solutions to patients and their loved ones," said Dr. Jeong Woo Cho, CEO of SK Biopharmaceuticals and SK Inc.

About Cala

Cala is a bioelectronic medicine company transforming the standard of care for chronic disease. The company's wearable neuromodulation therapies merge innovations in neuroscience and technology to deliver individualized peripheral nerve stimulation, and its vertically integrated commercial model is reshaping the delivery of prescription therapies. Cala's lead product, Cala TAPS therapy, is the only non-invasive prescription therapy for essential tremor. New therapies are under development in Parkinson's disease and other indications in neurology, as well as targets in psychiatry, cardiology and autoimmune disorders. The company is headquartered in the San Francisco Bay Area and backed by leading investors in both healthcare and technology.

Indication: Cala Trio therapy is indicated to aid in the temporary relief of hand tremors in the treated hand following stimulation in adults with essential tremor.

Caution: Federal law restricts this device to sale by or on the order of a physician.

Prior to use, refer to the product labeling for complete product instructions for use, contraindications, warnings, and precautions at <https://calatrio.com/Safety>.

About SK Biopharmaceuticals Co., Ltd. and SK Life Science, Inc.

SK Biopharmaceuticals and its U.S. subsidiary SK life science are pharmaceutical companies focused on the global research, development and commercialization of treatments for disorders of the central nervous system (CNS). The companies have two approved medicines and a diverse pipeline of compounds in development for the treatment of CNS disorders including epilepsy. Additionally, SK Biopharmaceuticals is focused on the discovery of new treatments in oncology. For more information, visit SK Biopharmaceuticals' website at www.skbp.com/eng and SK life science's website at www.SKLifeScienceInc.com.

###

Contact:

Sydney Sonnevile 815.307.6511

calahealth@highwirepr.com

MKG-1592 Rev A May 2022